Endovascular baroreflex amplification and the effect on sympathetic nerve activity in patients with resistant hypertension: A proof-of-principle study

• Published in: PloS one Vol. 16; no. 11; p. e0259826
• Main Authors: van Kleef, Monique E A M, Heusser, Karsten, Diedrich, André, Oey, P Liam, Tank, Jens, Jordan, Jens, Blankestijn, Peter J, Williams, Bryan, Spiering, Wilko
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 16-11-2021; Public Library of Science (PLoS)
• Subjects: Adult; Aerospace medicine; Amplification; Antihypertensives; Baroreceptors; Baroreflex; Biology and Life Sciences; Blood pressure; Bursts; Cardiovascular system; Carotid arteries; Complications and side effects; Confidence intervals; Development and progression; Diagnosis; Endovascular Procedures - instrumentation; Engineering and Technology; Female; Heart rate; Humans; Hypertension; Hypertension - physiopathology; Hypertension - surgery; Male; Medical examination; Medical imaging; Medicine; Medicine and Health Sciences; Microneurography; Middle Aged; Muscles; Nephrology; Nervous system, Sympathetic; Patients; Proof of Concept Study; Reflexes; Regulation; Sensitivity; Software; Sympathetic nerves; Sympathetic Nervous System - physiopathology; Treatment Outcome; Veins & arteries; United Kingdom; United States > US; Netherlands; Germany
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0259826

First in human studies suggest that endovascular baroreflex amplification (EVBA) lowers blood pressure (BP). To explore potential mechanisms for BP reduction, this study examines the effects of EVBA on muscle sympathetic nerve activity (MSNA) and baroreceptor sensitivity (BRS).
In a single-center sub-study of the CALM-DIEM study (Controlling And Lowering blood pressure with the MobiusHD-Defining Efficacy Markers), 14 patients with resistant hypertension were treated with EVBA. Microneurography and non-invasive continuous BP measurements were performed at baseline and three months after MobiusHD implantation. The primary outcome was change in MSNA. Secondary outcomes were change in baroreflex sensitivity (BRS), cardiovascular responses to a sympathetic stimulus, BP, heart rate (HR) and heart rate variability (HRV).
The primary endpoint was obtained in 10 of 14 patients enrolled in the sub-study. MSNA burst frequency and burst incidence decreased in 6 of 10 patients: mean change -4.1 bursts/min (95% confidence interval -12.2 to 4.0) and -3.8 bursts/100 heartbeats (-15.2 to 7.7). MSNA spike frequency and spike count decreased in 8 of 10 patients: mean change -2.8 spikes/sec (-7.3 to 1.8) and -3.0 spikes/heartbeat (-6.1 to 0.1). Change in MSNA and BP were not correlated. Office BP decreased by -14/-6 mmHg (-27 to -2/-15 to 3). We observed a trend towards decreased HR (-5 bpm, -10 to 1) and increased total power HRV (623 msec2, 78 to 1168). In contrast, BRS and cardiovascular responses remained unchanged after EVBA.
In this proof-of-principle study, EVBA did not significantly decrease MSNA in patients with resistant hypertension. EVBA did not impair baroreflex function.
Clinical trial registration at NCT02827032.